肝脑病的性别差异:解决知识差距
Lucia Lapenna1, Manuela Merli1, Marta Cilla2
1Department of Translational and Precision Medicine, Sapienza University of Rome, Italy.
概括
肝脏脑病 (HE) 中的性别差异尚未得到充分研究. 本综述强调了男性和女性在高等教育普及率,进展和结果方面的潜在差异,强调需要针对性别的研究和管理策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 神经科学是一个神经科学.
- 医学中的性别和性别.
背景情况:
- 肝脑病 (HE) 是肝病的严重并发症,影响患者的生活质量和医疗保健.
- 现有的高等教育研究主要忽略了其流行病学,临床表现和潜在机制的潜在基于性别的差异.
研究的目的:
- 审查和综合有关肝脏脑病的性别差异的当前知识.
- 探索流行病学趋势,临床表现,以及可能导致这些差异的生物学和心理社会机制.
- 确定研究差距,并倡导在高等教育管理中采取性别特异性的方法.
主要方法:
- 这篇叙事评论是由意大利肝脏研究协会 (AISF) 的"肝病学中的性别"特别兴趣小组 (SIG) 进行的.
- 该综述综合了有关高等教育性别差异的现有文献,包括流行病学数据,临床观察和新出现的机制性见解.
主要成果:
- 初步证据表明,男性和女性之间的HE流行率,风险因素和疾病进展可能存在差异.
- 有限的研究存在于性别特异性结果,治疗坚持和HE的心理影响.
- 来自人体组成,肠道微生物群研究和实验模型的新兴数据表明,这些性别差异背后存在潜在的生物学途径.
结论:
- 关于肝脏脑病的性别差异,仍然存在重大知识差距.
- 需要有针对性的研究来阐明这些差异,并制定性别特定的管理策略.
- 采用个性化医疗方法,将性考虑在内,对于改善卫生保健结果至关重要.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
01:22Cerebral Edema ll: Pathophysiology
31
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
31
01:29Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71